Clinical Trial Detail

NCT ID NCT03515512
Title IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Massachusetts General Hospital
Indications

myelodysplastic syndrome

chronic myelomonocytic leukemia

acute myeloid leukemia

Therapies

Enasidenib

Age Groups: senior adult

Additional content available in CKB BOOST